These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 11566456)
21. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. Lee AY; Rickles FR; Julian JA; Gent M; Baker RI; Bowden C; Kakkar AK; Prins M; Levine MN J Clin Oncol; 2005 Apr; 23(10):2123-9. PubMed ID: 15699480 [TBL] [Abstract][Full Text] [Related]
22. Low-molecular-weight-heparins as periprocedural anticoagulation for patients on long-term warfarin therapy: a standardized bridging therapy protocol. Jaffer AK; Ahmed M; Brotman DJ; Bragg L; Seshadri N; Qadeer MA; Klein A J Thromb Thrombolysis; 2005 Aug; 20(1):11-6. PubMed ID: 16133889 [TBL] [Abstract][Full Text] [Related]
23. Assessment of venous thromboembolism treatment in patients with cancer on low molecular weight heparin, warfarin, and the direct oral anticoagulants. Uppuluri EM; Burke KR; Haaf CM; Shapiro NL J Oncol Pharm Pract; 2019 Mar; 25(2):261-268. PubMed ID: 28942721 [TBL] [Abstract][Full Text] [Related]
24. RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty. RD Heparin Arthroplasty Group. J Bone Joint Surg Am; 1994 Aug; 76(8):1174-85. PubMed ID: 8056798 [TBL] [Abstract][Full Text] [Related]
25. Tinzaparin in outpatients with pulmonary embolism or deep vein thrombosis. Dager WE; King JH; Branch JM; Chow SL; Ferrer RE; Pak S; Togioka PY; White RH Ann Pharmacother; 2005; 39(7-8):1182-7. PubMed ID: 15956232 [TBL] [Abstract][Full Text] [Related]
26. Venous thromboembolism in lymphoma: how effectively are we treating patients? Muslimani AA; Spiro TP; Chaudhry AA; Taylor HC; Daw HA Am J Clin Oncol; 2009 Oct; 32(5):521-3. PubMed ID: 19546801 [TBL] [Abstract][Full Text] [Related]
27. Community-based treatment of venous thromboembolism with a low-molecular-weight heparin and warfarin. Hyers TM; Spyropoulos AC; J Thromb Thrombolysis; 2007 Dec; 24(3):225-32. PubMed ID: 17334932 [TBL] [Abstract][Full Text] [Related]
28. Current management of acute symptomatic deep vein thrombosis. Heit JA Am J Cardiovasc Drugs; 2001; 1(1):45-50. PubMed ID: 14728051 [TBL] [Abstract][Full Text] [Related]
29. Hospitalizations and Other Health Care Resource Utilization Among Patients with Deep Vein Thrombosis Treated with Rivaroxaban Versus Low-molecular-weight Heparin and Warfarin in the Outpatient Setting. Deitelzweig S; Laliberté F; Crivera C; Germain G; Bookhart BK; Olson WH; Schein J; Lefebvre P Clin Ther; 2016 Aug; 38(8):1803-1816.e3. PubMed ID: 27491278 [TBL] [Abstract][Full Text] [Related]
30. Single-center, retrospective evaluation of safety and efficacy of direct oral anticoagulants versus low-molecular-weight heparin and vitamin K antagonist in patients with cancer. Pritchard ER; Murillo JR; Putney D; Hobaugh EC J Oncol Pharm Pract; 2019 Jan; 25(1):52-59. PubMed ID: 28825375 [TBL] [Abstract][Full Text] [Related]
31. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study. Brekelmans MP; Ageno W; Beenen LF; Brenner B; Buller HR; Chen CZ; Cohen AT; Grosso MA; Meyer G; Raskob G; Segers A; Vanassche T; Verhamme P; Wells PS; Zhang G; Weitz JI Lancet Haematol; 2016 Sep; 3(9):e437-45. PubMed ID: 27570090 [TBL] [Abstract][Full Text] [Related]
32. Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: a meta-analysis. Couturaud F; Julian JA; Kearon C Thromb Haemost; 2001 Oct; 86(4):980-4. PubMed ID: 11686355 [TBL] [Abstract][Full Text] [Related]
33. How do palliative physicians manage venous thromboembolism? Johnson MJ; Sherry K Palliat Med; 1997 Nov; 11(6):462-8. PubMed ID: 9519169 [TBL] [Abstract][Full Text] [Related]
34. The use of long-term low-molecular weight heparin for the treatment of venous thromboembolism in palliative care patients with advanced cancer: a case series of sixty two patients. Noble SI; Hood K; Finlay IG Palliat Med; 2007 Sep; 21(6):473-6. PubMed ID: 17846086 [TBL] [Abstract][Full Text] [Related]
35. A single center retrospective cohort study comparing low-molecular-weight heparins to direct oral anticoagulants for the treatment of venous thromboembolism in patients with cancer - A real world experience. Phelps MK; Wiczer TE; Erdeljac HP; Van Deusen KR; Porter K; Philips G; Wang TF J Oncol Pharm Pract; 2019 Jun; 25(4):793-800. PubMed ID: 29460705 [TBL] [Abstract][Full Text] [Related]
36. Dalteparin versus warfarin for the prevention of recurrent venous thromboembolic events in cancer patients: a pharmacoeconomic analysis. Dranitsaris G; Vincent M; Crowther M Pharmacoeconomics; 2006; 24(6):593-607. PubMed ID: 16761906 [TBL] [Abstract][Full Text] [Related]
37. Recurrent venous thromboembolism in a Spanish population: incidence, risk factors, and management in a hospital setting. Grau E; Real E; Medrano J; Pastor E; Selfa S Thromb Res; 1999 Dec; 96(5):335-41. PubMed ID: 10605948 [TBL] [Abstract][Full Text] [Related]
38. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. ; Büller HR; Gent M; Gallus AS; Ginsberg J; Prins MH; Baildon R N Engl J Med; 1997 Sep; 337(10):657-62. PubMed ID: 9280815 [TBL] [Abstract][Full Text] [Related]
39. Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin. Fitzgerald RH; Spiro TE; Trowbridge AA; Gardiner GA; Whitsett TL; O'Connell MB; Ohar JA; Young TR; J Bone Joint Surg Am; 2001 Jun; 83(6):900-6. PubMed ID: 11407799 [TBL] [Abstract][Full Text] [Related]
40. Heparin and low-molecular-weight heparin therapy for venous thromboembolism. The twilight of anticoagulant monitoring. Hull RD; Pineo GF; Stein P Int Angiol; 1998 Dec; 17(4):213-24. PubMed ID: 10204652 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]